EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access

Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study

Jian Lu, Shuaigang Sun, Xinru Shang, Shimin Jiang, Zekai Deng, Shunwei Wang, Chenping Wei, Jiaqi Hu, Wenge Li

International Journal of Medical Sciences · 11.05.2026 · 23 (7) · 2197-2208

DOI: 10.7150/ijms.133077 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift International Journal of Medical Sciences, erschienen am 11.05.2026. Verfasst von Jian Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Metabolic Syndrome, Hypoglycemic Agents, Diabetes Mellitus, Type 2, Cardio-Renal Syndrome. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeHypoglycemic AgentsDiabetes Mellitus, Type 2Cardio-Renal SyndromeCardiovascular DiseasesHumansMendelian Randomization AnalysisSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinInsulin SecretagoguesMetforminPPAR-gamma AgonistsSulfonylurea CompoundsGenome-Wide Association StudyGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP-1 receptor agonistsMendelian randomizationSGLT2 inhibitorscardiovascular-kidney-metabolic syndromeglucose-lowering drugs

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsGlycated HemoglobinInsulin SecretagoguesMetforminhemoglobin A1c protein, humanPPAR-gamma AgonistsSulfonylurea CompoundsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Nephrology, China-Japan Friendship Hospital, Beijing, China.
  • Department of Nephrology, Capital Medical University China-Japan Friendship School of Clinical Medicine, Beijing, China.
  • Department of Nephrology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
  • School of Basic Medical Sciences, Capital Medical University, Beijing, China.
  • School of Public Health, Capital Medical University, Beijing, China.
  • School of Healthcare Management, Tsinghua Medicine, Tsinghua University, Beijing, China.

Zitieren

APA

Lu, J., Sun, S., Shang, X., Jiang, S., Deng, Z., Wang, S., Wei, C., Hu, J., & Li, W. (2026). Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study. International Journal of Medical Sciences, 23(7), 2197-2208. https://doi.org/10.7150/ijms.133077

Vancouver

Lu J, Sun S, Shang X, Jiang S, Deng Z, Wang S, et al. Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study. International Journal of Medical Sciences. 2026;23(7):2197-2208. doi:10.7150/ijms.133077

BibTeX
@article{Lu2026,
  author = {Lu, Jian and Sun, Shuaigang and Shang, Xinru and Jiang, Shimin and Deng, Zekai and Wang, Shunwei and Wei, Chenping and Hu, Jiaqi and Li, Wenge},
  title = {Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study},
  journal = {International Journal of Medical Sciences},
  year = {2026},
  volume = {23},
  number = {7},
  pages = {2197--2208},
  doi = {10.7150/ijms.133077}
}
Kostenlos starten →